This research study aims to better understand patient experiences with accessing genetic counseling services for hypermobile Ehlers-Danlos syndrome (hEDS). The study will include a review of MUSC medical records to better understand referral patterns to genetic counseling services among patients with hEDS. Patients with hEDS will also be asked to complete a survey about their experiences with accessing genetic counseling services. Healthcare providers will be asked to complete a separate survey about their experiences referring patients with hEDS to genetic counseling services and potential factors that may influence the referral process. The surveys will take approximately 10-15 minutes to complete.

There are minimal risks to participants but may include possible loss of confidentiality or discomfort when answering questions related to healthcare experiences. There is no direct benefit to participants, but the information provided may help improve access to genetic counseling services for future patients with hEDS. Participation in the surveys is completely voluntary.

The 12 week study is designed to assess the efficacy and safety of the twice daily ALKS2680, in narcolepsy Type 2. Administered upon wakening and a second time 3-5 hours later, 3 different doses will be compared to a placebo. The effects of ALKS2680 on excessive daytime sleepiness and sleep quality will be examined during overnight and daytime sleep studies.

The 12 week study is designed to assess the efficacy and safety of the twice daily ALKS2680, in narcolepsy Type 1. Administered upon wakening and a second time 5-7 hours later, 2 different doses (6mg and 10mg) will be compared to a placebo. The effects of ALKS2680 on excessive daytime sleepiness and sleep quality will be examined during overnight and daytime sleep studies.

This study is for patients diagnosed with a solid tumor malignancy of any stage and identified as high risk (having a 6-month mortality estimate). The study is evaluating A-PACT (algorithm-Enables Patients Activated in Cancer Care through Teams). The subjects will be randomized (like flipping a count) to determine if they will receive A-PACT with usual care or usual care alone. The primary purpose of this study is to determine if the A-PACT Program reduces unplanned hospital visits and improves communication between patients and their health care team. Participants in this study can expect to be in this study for 12 months or their withdrawal of consent.

A 95-week study comparing the efficacy and safety of a specific dose of a trial product named zenagamtide versus two different doses of semaglutide, administered once weekly via injection along with a reduced-calorie diet and increased physical activity on weight management in participants with obesity.

This study is for patients who have undergone surgery for non-small cell lung cancer (NSCLC), and your doctors have found that some cancer may still be present in nearby lymph nodes. The study is being done to figure out if adding radiation therapy after surgery can help lower the chance of lung cancer coming back while keeping side effects at a safe level.

The study is being done to find out if this approach is better or worse than the usual approach for your non-small cell lung cancer (NSCLC) after surgery. The usual approach is defined as care most people get for non-small cell lung cancer and is approved by the Food and Drug Administration (FDA).

If you decide to take part in this study, you will either get chemotherapy or immunotherapy or you will get chemotherapy or immunotherapy plus an additional type of radiation therapy called I²-PORT for up to 24 months

After you finish your treatment, your doctor and study team will continue to follow your condition for side effects and cancer recurrence. Follow-up visits will be every 3 months for 2 years and every 6 months for 3 more years, totaling 5 years of follow-up.

There is evidence that I²-PORT radiation therapy is effective in reducing the risk of cancer returning in certain patients with lung cancer. It is not possible to know now if this approach will extend your time without disease compared to the usual approach. This study will help the study doctors learn things that will help people in the future.

If you choose to take part in this study, there is a risk that the I²-PORT radiation therapy may not be as good as the usual approach for your cancer at preventing your cancer from coming back. Some of the most common side effects that the study doctors know about are reddening, tanning, mild pain, hair loss in treated area, and or tiredness. There may be some risks that the study doctors do not yet know about.

Glaucoma is the leading cause of permanent blindness in the world, often due to the intraocular pressure in your eye (IOP) becoming too high. Cataracts are the cloudy lenses inside your eye that are common after age 40 and often require surgery to replace the cloudy lens with an intraocular implant (IOL). This study will evaluate the safety and IOP-lowering effectiveness of the DF12 Canaloplasty and Trabeculotomy Surgical System. This device combines two glaucoma surgical procedures (Canaloplasty and Trabeculotomy) in patients that are having their cataracts removed. The endpoint for this study is the reduction in IOP without the use of topical (often eye drops) or oral glaucoma medications at 12 months.

This study aims to learn how adolescents and young adults who received a liver transplant as children think about their transplant and prepare to manage their healthcare as they get older. Participants will complete questionnaires and may take part in an interview about their experiences, feelings, and healthcare responsibilities. The study will explore how young people view their transplant, how it fits into their sense of self, and how these factors relate to their readiness for adult healthcare. Information from this study will help researchers better understand the needs of young liver transplant recipients and guide the development of future support programs.

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

This study is for people with advanced head and neck cancer who cannot receive cisplatin. The purpose of this study is to compare treating head and neck cancer with radiation plus cetuximab versus radiation plus chemotherapy (carboplain and paclitaxel). Carboplatin, paclitaxel, and cetuximab are approved by the FDA to treat head and neck cancer.

If you agree to take part, we expect that your participation in this study may last up to 3 years. This includes visits to the clinic after you finish all study treatments. These follow-up visits will take place about every 2 months during the 1st year and about every 4 months thereafter.

Risks may include nausea, vomiting, headache, feeling tired, loss of appetite, and hair loss. Participants may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.